Chipcare started as a spin-out from the University of Toronto.
Chipcare received an Angel seed investment and grant for the development of a ruggedized handheld point-of-care platform for monitoring CD3+/CD4+ white blood cell counts in HIV patients on ART (antiretroviral therapy) in global health settings (initially Sub-Saharan Africa).
The company implemented a QMS (Quality Management System) in 2015 and continues to maintain registration to ISO 13485.
With the support of a WHO (World Health Organization) technical committee, Chipcare established a regulatory plan to enable the platform to obtain WHO pre-qualification.
The company completed a series A financing round in early 2015 to complete the development of the platform and to fund initial pilot builds. Results from feasibility studies surpassed the target product profile requirements.
Chipcare developed a new strategy to leverage and expand the core optical-based detection technology to enable the platform to perform higher multiplexed assays including nucleic acid-based assays, immunoassays and cell-based assays. The company has successfully obtained non-dilutive funding through various grants and government programs.
Despite the COVID-19 pandemic, Chipcare is diligently working on bringing its final commercial product to market in 2022!
Chipcare has the resources, expertise and facilities to bring our solution to market and to provide real patient impact.
Copyright © 2021. All rights reserved.